8-K: Sangamo Therapeutics Faces Nasdaq Delisting, Moves to OTCQB

Sangamo Therapeutics has received a delisting notice from Nasdaq due to a sustained low stock bid price and will transition to the OTCQB Venture Market.

Summary

• Sangamo Therapeutics, Inc. received a delisting notice from Nasdaq on April 28, 2026, due to its common stock failing to meet the minimum bid price requirement of $1.00 for 30 consecutive business days.
• The company was previously granted an extension until April 27, 2026, to regain compliance, but failed to do so.
• Trading of Sangamo's common stock on Nasdaq Capital Market will be suspended starting May 5, 2026.
• The company plans to appeal the delisting determination by requesting a hearing before a Nasdaq Hearings Panel.
• A timely hearing request will stay the delisting but not the trading suspension.
• Sangamo has secured approval to be quoted on the OTCQB Venture Market, operated by OTC Markets Group.
• Trading on the OTCQB is expected to commence on May 5, 2026, under the existing symbol SGMO.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the Nasdaq delisting notice, which signals significant challenges in meeting exchange listing standards and potential implications for investor confidence and market access.

Positives

• Secured approval to trade on the OTCQB Venture Market, ensuring continued trading access for investors.
• Expects trading to commence on OTCQB on May 5, 2026, under the existing symbol SGMO, minimizing disruption.

Negatives

• Received a formal delisting notice from Nasdaq due to failure to meet the minimum bid price requirement.
• Trading on the Nasdaq Capital Market will be suspended effective May 5, 2026.
• The company has not regained compliance with Nasdaq's minimum bid price rule.

Risks

• The Nasdaq Hearings Panel may uphold the delisting determination, preventing reinstatement of trading on Nasdaq.
• The OTCQB Venture Market may have lower liquidity and investor visibility compared to Nasdaq.
• The ongoing failure to meet listing requirements indicates underlying business or market challenges.
• Forward-looking statements regarding the hearing and OTCQB trading are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to commence trading on the OTCQB Venture Market on May 5, 2026, and is requesting a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The outcome of the hearing is uncertain.

Management Comments

• The Company plans to request a hearing before a Nasdaq Hearings Panel (the Panel) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series for the purpose of appealing the Staffs delisting determination.

Industry Context

StockSavvy.ai notes that Nasdaq delistings, particularly for biotech firms reliant on capital markets for R&D funding, can signal significant financial distress or a need for strategic restructuring. Transitioning to an over-the-counter market often reflects a company's inability to meet the stringent listing requirements of major exchanges, potentially impacting investor confidence and access to capital.

Stakeholder Impact

• Shareholders: Potential decrease in stock liquidity and market visibility, possible impact on stock price due to trading on OTCQB.
• Employees: Uncertainty regarding company stability and future prospects, potential impact on morale.
• Creditors: Increased risk perception due to the company's financial standing indicated by delisting.

Next Steps

• Request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination.
• Commence trading on the OTCQB Venture Market on May 5, 2026.
• Await the decision of the Nasdaq Hearings Panel regarding the appeal.

Key Dates

Recommendation

While the Nasdaq delisting is a significant negative, the company is actively pursuing an appeal and has secured a listing on the OTCQB, ensuring continued trading. Investors should hold to see the outcome of the Nasdaq appeal and the performance on the OTCQB, rather than selling based solely on the delisting notice.

Keywords

Nasdaq Delisting, Sangamo Therapeutics, OTCQB Venture Market, Minimum Bid Price Requirement, Stock Suspension, SEC Filing, Form 8-K, Biotechnology